ReviewJournal of labelled compounds & radiopharmaceuticals2019
Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples.
Review in Journal of labelled compounds & radiopharmaceuticals, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Bimodal nanobody agents for cancer imaging and potential intraoperative guidance: a systematic review.Journal of nanobiotechnology · 2026Pooled it
- Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting.RSC advances · 2026Article
- How Regulation 536/2014 Is Changing Academic Research with Therapeutic Radiopharmaceuticals: A Local Experience.Pharmaceuticals (Basel, Switzerland) · 2025Article
- S-values for bone marrow dosimetry in preclinical radiopharmaceutical studies with rodents.EJNMMI physics · 2025Article
- Hyperpolarized MRI theranostics in cancer.Frontiers in oncology · 2025Article
- Emerging Applications of EpCAM-Targeted Nuclear Medicine Probes: Current Research and Future Perspectives.International journal of nanomedicine · 2025Review
- Radiopharmaceutical small-scale preparation in Europe: will we be able to harmonize the situation?EJNMMI radiopharmacy and chemistry · 2024Review
- EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials.European journal of nuclear medicine and molecular imaging · 2024Article
- A review of metallic nanoparticles: present issues and prospects focused on the preparation methods, characterization techniques, and their theranostic applications.Frontiers in chemistry · 2024Review
- Radiochemical and Biological Evaluation of 3p-Pharmaceuticals (Basel, Switzerland) · 2023Article
- Automated Radiosynthesis, Preliminary In Vitro/In Vivo Characterization of OncoFAP-Based Radiopharmaceuticals for Cancer Imaging and Therapy.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals.EJNMMI radiopharmacy and chemistry · 2022Review
- One stone, many birds: Recent advances in functional nanogels for cancer nanotheranostics.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Comparison of absorbed dose extrapolation methods for mouse-to-human translation of radiolabelled macromolecules.EJNMMI research · 2022Article
- Exploring the translational challenge for medical applications of ionising radiation and corresponding radiation protection research.Journal of translational medicine · 2022Article
- Cold Kit Labeling: The Future ofFrontiers in medicine · 2022Review
- Radiopharmaceutical Formulation and Preclinical Testing ofPharmaceuticals (Basel, Switzerland) · 2021Article
- Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [Journal of labelled compounds & radiopharmaceuticals · 2021Article
- Non-oncological applications of RGD-based single-photon emission tomography and positron emission tomography agents.European journal of nuclear medicine and molecular imaging · 2021Review
- Emerging Radionuclides in a Regulatory Framework for Medicinal Products - How Do They Fit?Frontiers in medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 5 countries.
Funding
Abstract
With the development of ever more radiopharmaceuticals suitable for theranostic applications, translation of novel compounds from the preclinical stage towards clinical application becomes a bottleneck for the advances in Nuclear Medicine. This review article summarizes the current regulatory framework for clinical trials with radiopharmaceuticals in the European Union, provides a general overview of the documentation required, and addresses quality, safety, and clinical aspects to be considered. By using a recent successful example of translating a theranostic peptide radioligand, namely
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.